Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.40 |
| ▸ | GLP1R | P43220 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329533 | 1.00 | TLR2 (0.53) | TLR2CPB1CPB2KMT2AMDM2 | |
| SCHEMBL16329552 | 0.97 | TLR2 (0.54) | TLR2CPB1CPB2KMT2AMDM2 | |
| SCHEMBL30895594 | 0.92 | TLR2 (0.50) | TLR2CPB1CPB2KMT2AMDM2 | |
| SCHEMBL19542141 | 0.92 | TLR2 (0.62) | TLR2KMT2AGLP1R | |
| SCHEMBL19542037 | 0.91 | TLR2 (0.49) | TLR2CPB1CPB2KMT2AGLP1R | |
| SCHEMBL19542143 | 0.90 | TLR2 (0.49) | TLR2KMT2A | |
| SCHEMBL19542209 | 0.88 | TLR2 (0.56) | TLR2CPB1CPB2KMT2A | |
| SCHEMBL22514287 | 0.88 | TLR2 (0.54) | TLR2CPB1CPB2KMT2A | |
| SCHEMBL19541911 | 0.88 | TLR2 (0.56) | TLR2CPB1CPB2KMT2A | |
| SCHEMBL30895420 | 0.86 | KMT2A (0.52) | TLR2KMT2AMDM2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | BTD, IDUA, DNPEP | TLR2 961/4885CPB1 587/4885CPB2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.